115 related articles for article (PubMed ID: 2380099)
1. Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of a rat glioma.
Deutsch M; Rewers AB; Redgate S; Fisher ER; Boggs SS
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):85-7. PubMed ID: 2380099
[TBL] [Abstract][Full Text] [Related]
2. 5-Iodo-2-deoxyuridine administered into the lateral cerebral ventricle as a radiosensitizer in the treatment of disseminated glioma.
Deutsch M; Rewers AB; Redgate ES; Fisher ER; Boggs SS
J Natl Cancer Inst; 1989 Sep; 81(17):1322-5. PubMed ID: 2769785
[TBL] [Abstract][Full Text] [Related]
3. Intracerebral delivery of 5-iodo-2'-deoxyuridine in combination with synchrotron stereotactic radiation for the therapy of the F98 glioma.
Rousseau J; Adam JF; Deman P; Wu TD; Guerquin-Kern JL; Gouget B; Barth RF; Estève F; Elleaume H
J Synchrotron Radiat; 2009 Jul; 16(Pt 4):573-81. PubMed ID: 19535873
[TBL] [Abstract][Full Text] [Related]
4. Enhancement radiation-induced apoptosis in C6 glioma tumor-bearing rats via pH-responsive magnetic graphene oxide nanocarrier.
Shirvalilou S; Khoei S; Khoee S; Mahdavi SR; Raoufi NJ; Motevalian M; Karimi MY
J Photochem Photobiol B; 2020 Apr; 205():111827. PubMed ID: 32120183
[TBL] [Abstract][Full Text] [Related]
5. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
6. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
7. 5-[125]iodo-2'-deoxyuridine in the radiotherapy of solid CNS tumors in rats.
Kassis AI; Adelstein SJ
Acta Oncol; 1996; 35(7):935-9. PubMed ID: 9004774
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
9. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres.
Gabikian P; Tyler BM; Zhang I; Li KW; Brem H; Walter KA
J Neurosurg; 2014 May; 120(5):1078-85. PubMed ID: 24605841
[TBL] [Abstract][Full Text] [Related]
11. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
12. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats.
Kassis AI; Wen PY; Van den Abbeele AD; Baranowska-Kortylewicz J; Makrigiorgos GM; Metz KR; Matalka KZ; Cook CU; Sahu SK; Black PM; Adelstein SJ
J Nucl Med; 1998 Jul; 39(7):1148-54. PubMed ID: 9669385
[TBL] [Abstract][Full Text] [Related]
13. IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas.
Yuan X; Dillehay LE; Williams JR; Shastri VR; Williams JA
Int J Cancer; 2001 Apr; 96(2):118-25. PubMed ID: 11291095
[TBL] [Abstract][Full Text] [Related]
14. Development of a magnetic nano-graphene oxide carrier for improved glioma-targeted drug delivery and imaging: In vitro and in vivo evaluations.
Shirvalilou S; Khoei S; Khoee S; Raoufi NJ; Karimi MR; Shakeri-Zadeh A
Chem Biol Interact; 2018 Nov; 295():97-108. PubMed ID: 30170108
[TBL] [Abstract][Full Text] [Related]
15. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12).
Urtasun RC; Cosmatos D; DelRowe J; Kinsella TJ; Lester S; Wasserman T; Fulton DS
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):207-14. PubMed ID: 8407393
[TBL] [Abstract][Full Text] [Related]
16. Time of death of CNS tumor-bearing rats can be reliably predicted by body weight-loss patterns.
Redgate ES; Deutsch M; Boggs SS
Lab Anim Sci; 1991 Jun; 41(3):269-73. PubMed ID: 1658469
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases.
Sahu SK; Wen PY; Foulon CF; Nagel JS; Black PM; Adelstein SJ; Kassis AI
J Nucl Med; 1997 Mar; 38(3):386-90. PubMed ID: 9074525
[TBL] [Abstract][Full Text] [Related]
18. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.
Rebischung C; Hoffmann D; Stefani L; Desruet MD; Wang K; Adelstein SJ; Artignan X; Vincent F; Gauchez AS; Zhang H; Fagret D; Vuillez J; Kassis AI; Balosso J
Int J Radiat Biol; 2008 Dec; 84(12):1123-9. PubMed ID: 19061137
[TBL] [Abstract][Full Text] [Related]
19. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy.
Alvarez D; Hogstrom KR; Brown TA; Ii KL; Dugas JP; Ham K; Varnes ME
Radiat Res; 2014 Dec; 182(6):607-17. PubMed ID: 25409122
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
Kassis AI; Adelstein SJ; Mariani G
Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]